Cargando…
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia
The histone demethylase lysine-specific demethylase 1 (LSD1 or KDM1A) has emerged as a candidate therapeutic target in acute myeloid leukaemia (AML); tranylcypromine-derivative inhibitors induce loss of clonogenic activity and promote differentiation, in particular in the MLL-translocated molecular...
Autores principales: | Deb, Gauri, Wingelhofer, Bettina, Amaral, Fabio M. R., Maiques-Diaz, Alba, Chadwick, John A., Spencer, Gary J., Williams, Emma L., Leong, Hui-Sun, Maes, Tamara, Somervaille, Tim C. P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192845/ https://www.ncbi.nlm.nih.gov/pubmed/31780813 http://dx.doi.org/10.1038/s41375-019-0659-6 |
Ejemplares similares
-
LSD1: biologic roles and therapeutic targeting
por: Maiques-Diaz, Alba, et al.
Publicado: (2016) -
LSD1 inhibitors disrupt the GFI1 transcription repressor complex
por: Maiques-Diaz, Alba, et al.
Publicado: (2018) -
HMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block
por: Maiques-Diaz, Alba, et al.
Publicado: (2022) -
Tuning mTORC1 activity dictates the response of acute myeloid leukemia to LSD1 inhibition
por: Abdel-Aziz, Amal Kamal, et al.
Publicado: (2020) -
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission
por: De Gregorio, Danilo, et al.
Publicado: (2021)